Home › Funds › Eversept Partners, LP › UTHR
Eversept Partners, LP position in UTHR
UNITED THERAPEUTICS CORP DEL · Health Care
Eversept Partners, LP reported holding 287,668 shares of UTHR (UNITED THERAPEUTICS CORP DEL) in its Q2 2026 13F filing — a position valued at US$155.9M, representing 8.15% of its reported portfolio and ranking #1 among its reported holdings. Eversept Partners, LP has disclosed UTHR holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Eversept Partners, LP's UTHR position evolved
Eversept Partners, LP first disclosed a stake in UTHR in Q3 2023 at 267,903 shares (US$60.5M). The position peaked in Q1 2026 at 264,271 shares, worth US$156.7M. Across 12 filings, Eversept Partners, LP increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 287,668 shares valued at US$155.9M — an increase of 23,397 shares quarter over quarter.. Notable position changes include a 67% trim in Q4 2024 (shares fell 11% over the following quarter), a 73% trim in Q3 2025 (shares rose 16% over the following quarter), a 1459% increase in Q4 2025 (shares rose 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 267.90K | $60.51M | New |
| Q4 2023 | 246.23K | $54.14M | Reduce |
| Q1 2024 | 251.13K | $57.69M | Add |
| Q2 2024 | 235.35K | $74.97M | Reduce |
| Q3 2024 | 130.95K | $46.93M | Reduce |
| Q4 2024 | 43.70K | $15.42M | Reduce |
| Q1 2025 | 57.49K | $17.72M | Add |
| Q2 2025 | 59.37K | $17.06M | Add |
| Q3 2025 | 16.20K | $6.79M | Reduce |
| Q4 2025 | 252.59K | $123.08M | Add |
| Q1 2026 | 264.27K | $156.71M | Add |
| Q2 2026 | 287.67K | $155.87M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About UTHR and 13F data
UTHR (UNITED THERAPEUTICS CORP DEL) is a Health Care company. 42 other funds we track also report a position in UTHR — the largest reported positions include Avoro Capital Advisors LLC (US$1.51B), Renaissance Technologies (US$925.8M), ASSETMARK, INC (US$338.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding UTHR
- Avoro Capital Advisors LLC 2.78M sh · $1.51B · Q2 2026
- Renaissance Technologies 1.71M sh · $925.85M · Q2 2026
- ASSETMARK, INC 624.07K sh · $338.14M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 457.00K sh · $247.62M · Q2 2026
- Vestal Point Capital, LP 435.00K sh · $235.70M · Q2 2026
More on Eversept Partners, LP
FAQ
How long has Eversept Partners, LP held UTHR?
Eversept Partners, LP has disclosed UTHR holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Eversept Partners, LP's current position in UTHR?
As of Q2 2026, Eversept Partners, LP holds 287.67K shares of UTHR (UNITED THERAPEUTICS CORP DEL), valued at $155.87M, representing 8.15% of its reported portfolio and ranking #1.
Has Eversept Partners, LP been buying or selling UTHR?
In the latest 13F filing (Q2 2026), Eversept Partners, LP increased its position in UTHR. The position peaked in Q1 2026 at 264.27K shares.
Which other funds hold UTHR?
Other major institutional holders of UTHR include Avoro Capital Advisors LLC, Renaissance Technologies, ASSETMARK, INC, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.